Welcome to our dedicated page for CompuMed news (Ticker: CMPD), a resource for investors and traders seeking the latest updates and insights on CompuMed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CompuMed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CompuMed's position in the market.
CompuMed, Inc. (OTC PINK:CMPD) announced the results of its shareholder meeting held on March 15, 2022, with 65.4% of eligible shares voted. Lee Keddie and Loren DenHerder received 98.0% support for their board candidacies. David Pointer garnered 96.4% approval. A reverse stock split proposal (1:25) received 89.3% approval, while the Equity Incentive plan was favored by 86.1%. The company is now finalizing documents for FINRA review and working with ComputerShare to implement these changes.
CompuMed, Inc. (CMPD) reported its fiscal 2022 first-quarter results with revenues of $1.54 million, up 4.6% year-over-year and 5.9% sequentially. Operating income increased to $121,000, a 12% rise from the previous year, although down from $495,000 in Q4 2021. Cash and accounts receivable totaled $2.8 million, reflecting an 8.5% decline from Q4 2021 due to timing of payments and equipment purchases. CompuMed emphasizes its long-term growth strategy despite short-term cash fluctuations.
CompuMed, Inc. (OTCPK: CMPD) reported strong financial results for the fourth quarter and fiscal year 2021. Revenue increased by 14.9% to $1.45 million in Q4 and 19.9% to $6.32 million annually. Net income rose significantly to $480,440 in Q4 and $1,067,152 for the full year. The company also announced a reverse stock split proposal and other shareholder votes aimed at enhancing liquidity and shareholder value, alongside a strategic accounting change that improved asset valuation.
CompuMed, Inc. (OTCPK: CMPD) has reported strong results for its fiscal 2021 third quarter. Revenue reached $1.76 million, marking an 8.2% sequential increase and a significant 55.1% rise year-over-year. Operating income also saw a robust increase to $250,000, up 56.8% sequentially and 150.2% year-over-year. The company expects overall full year revenue growth to approximate 20%. At the end of the quarter, CompuMed's cash and accounts receivable stood at $3.06 million, up 7.2% from the previous quarter and 21.2% from the previous year.